Table IV. Baseline Genotype and Viral Load Among the 15 Women with Single, Non- HPV 16 Carcinogenic HPV Infection and Incident ≥Cin2 During 7 Years of Follow-Up.
| HPV genotype | Hybridization Signal strength | Enrollment diagnosis | Final diagnosis |
|---|---|---|---|
| HPV 31 | 2 | Normal | CIN 2 |
| HPV 31 | 2 | Normal | CIN 2 |
| HPV 33 | 4 | Normal | CIN 2 |
| HPV 18 | 1 | Normal | CIN 3 |
| HPV 31 | 5 | Normal | CIN 3 |
| HPV 51 | 1 | Normal | CIN 3 |
| HPV 18 | 3 | Normal | CIN 3 |
| HPV 52 | 4 | Normal | CIN 3 |
| HPV 18 | 2 | Normal | cancer |
| HPV 33 | 5 | Equivocal | CIN 2 |
| HPV 31 | 2 | Equivocal | CIN 2 |
| HPV 33 | 4 | Equivocal | CIN 3 |
| HPV 33 | 3 | Equivocal | CIN 3 |
| HPV 35 | 5 | Equivocal | CIN 3 |
| HPV 35 | 2 | LSIL | CIN 3 |
Genotype and hybridization signal strength was measured at enrollment.